Products

Because time makes all the difference...

The BD GeneOhm™ MRSA test is the first rapid, molecular-based assay cleared by the FDA, Health Canada and bearing the CE Mark for the direct detection of methicillin- resistant Staphylococcus aureus (MRSA) from a nasal specimen. Test procedure time for the assay is under two hours. Compared to culture methods requiring two to five days, this rapid turn-around time can be used to enhance any infection control program. The test provides a definitive result in a single assay.

The BD GeneOhm™ MRSA test enables hospitals to dramatically improve the identification of MRSA, which can effectively result in the prevention and control of MRSA infections.

• Rapid turnaround time
• Clinical performance
• Can help to dramatically reduce healthcare costs
• Simple use directly from nasal swab
• Adaptable and easily incorporated into existing lab workflow

Assay Features: 

• Rapid, simultaneous detection and differentiation of MRSA and SA direct from positive blood culture bottles, wounds and nasal specimens.
• Results in less than 2 hours vs. 2-3 days required for traditional microbiology culture methods
• Simple user-friendly workflow
• Aids in the differentiation of MRSA/SA and potential contaminants such as coagulase negative Staphylococcus.

Clinical Advantages:

• Rapid identification and treatment of BSIs has been proven to reduce healthcare costs and improve patient outcomes
• Promotes faster, better antibiotic selection to prevent the emergence of vancomycin resistant organisms
• Facilitates earlier isolation of patients infected with MRSA to prevent further transmission and infection

Assay Features:

• Lab results in <2 hours for vancomycin resistance
• Aids in the rapid identification and differentiation of both vanA and vanB genes direct from perianal and/or rectal swabs
  • vanA and vanB are clinically relevant genes associated with vancomycin-resistant enterococci.
  • These genes are transferrable from organism to organism
• Simple, user-friendly work flow
  • Less time and labour required when compared to traditional culture method.

Clinical Advantages:

• Rapid identification of vancomycin-resistant organisms
• Facilitates early infection control intervention to prevent transmission and infection
• Prevention of VRE transmission and infection can save healthcare costs by decreasing hospital length of stay and the need for contact precautions

The Answer You Need Today
From a Single Test Result

Assay Features

• Performance comparable to the "gold standard" cytotoxicity assay
• Real-time PCR results in <2 hours for toxigenic C. difficile
• Specific detection of the tcdB gene found only in toxigenic C. difficile
• One single method that can replace current C. difficile testing

Clinical Advantages

• Rapid, sensitive and specific results for patients suspected of having C. difficile infection (CDI)
• Earlier accurate diagnosis enables appropriate treatment of infected patients and can help avoid empiric treatment and unnecessary exposure to antibiotics in negative patients
• Facilitates targeted infection control practices to prevent transmission and infection.